Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Aurisco Pharma Expands Yangzhou CRDMO Facility for Generic GLP-1 Peptides

publication date: Apr 5, 2024

Aurisco Pharmaceutical has completed the expansion of its cGMP peptide manufacturing site in Yangzhou that will offer multi-metric ton capacity to produce the company’s generic GLP-1 peptides. The facility, which expects to start operations in mid-2024, will initially pursue commercial scale validation of recombinant Semaglutide. The site also offers CRDMO services for synthetic and recombinant peptides and oligonucleotides. Established in 1998, Aurisco is headquartered in Zhejiang Tiantai, with an R&D center in Shanghai and facilities in Yangzhou, Tiantai, Hangzhou and Tianjin. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital